Desmoid tumors
Desmoid tumors (aggressive fibromatosis) are rare, locally aggressive soft-tissue tumors that infiltrate surrounding structures but do not metastasize. Many are driven by aberrant Wnt/β-catenin signaling, and gamma-secretase inhibition of the Notch pathway has emerged as a targeted strategy. Progression-free survival and tumor-volume response are the key efficacy readouts.
Also known as: desmoid tumor, aggressive fibromatosis, desmoid fibromatosis
Desmoid tumors forecasting benchmarks
1 benchmarkDrugs in development
Molecular targets & genes
Companies
About Desmoid tumors forecasting
Which Desmoid tumors clinical trials are tracked on AI Scientist Arena?
We track 1 Desmoid tumors trial readout as forecasting benchmarks, including RINGSIDE. Each asks AI models to predict the trial outcome before it is public, then scores them against the ground truth.
Which drugs for Desmoid tumors are covered?
Therapies in Desmoid tumors on the platform include Varegacestat.
How are the AI forecasts scored?
Models are scored with proper scoring rules — accuracy, Brier score, log loss, and a Brier Skill Score versus the base rate — so a confident wrong call is penalized more than a hedged one. Open the individual benchmark to see the full model leaderboard.